
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
AI Summary
- About


Hepion Pharmaceuticals Inc (HEPA)



- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)


(see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
02/14/2025: HEPA (1-star) is currently NOT-A-BUY. Pass it for now.
Analysis of Past Performance
Type Stock | Historic Profit -37% | Avg. Invested days 24 | Today’s Advisory PASS |
Upturn Star Rating ![]() ![]() | Upturn Advisory Performance ![]() | Stock Returns Performance ![]() |
![]() ![]() | ![]() ![]() |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 1.94M USD | Price to earnings Ratio - | 1Y Target Price 30 |
Price to earnings Ratio - | 1Y Target Price 30 | ||
Volume (30-day avg) 39400337 | Beta 1.65 | 52 Weeks Range 0.12 - 3.33 | Updated Date 02/15/2025 |
52 Weeks Range 0.12 - 3.33 | Updated Date 02/15/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -3.98 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -110.4% | Return on Equity (TTM) -288.27% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 4573229 | Price to Sales(TTM) - |
Enterprise Value 4573229 | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA -0.1 | Shares Outstanding 10619500 | Shares Floating 4834885 |
Shares Outstanding 10619500 | Shares Floating 4834885 | ||
Percent Insiders 15.27 | Percent Institutions 11.6 |
AI Summary
Hepion Pharmaceuticals Inc.: A Comprehensive Overview
Company Profile:
Detailed History and Background:
Hepion Pharmaceuticals Inc. (NASDAQ:HEPA) is a clinical-stage biopharmaceutical company founded in 2011 and headquartered in Morrisville, North Carolina. The company focuses on developing and commercializing proprietary therapeutics for chronic liver diseases with a high unmet medical need.
Description of the Company's Core Business Areas:
Hepion operates in the pharmaceutical industry, specifically focusing on:
- Antiviral therapeutics: Developing drugs to treat chronic hepatitis B virus (HBV) and other viral infections.
- Non-alcoholic steatohepatitis (NASH) therapeutics: Investigating treatments for this progressive liver disease.
Overview of the Company's Leadership Team and Corporate Structure:
- Dr. Robert Foster: Chairman, President, and CEO
- Dr. James Atkins: Executive Vice President and Chief Scientific Officer
- Dr. Diane Soffientini: Senior Vice President, Clinical Development
- Board of Directors: Includes experienced leaders from the biopharmaceutical industry.
Top Products and Market Share:
Top Products:
- Ciclopirox (CPX): An antifungal agent currently in Phase 2b clinical trials for the treatment of chronic HBV infection.
- Tigecycline: An antibiotic being investigated for the treatment of NASH.
Market Share:
Hepion currently has no marketed products and therefore does not currently hold a market share.
Comparison of Product Performance and Market Reception against Competitors:
It is not yet possible to compare Hepion's products directly to competitors' products as they are still in the clinical trial phase. However, based on early data, CPX shows promising efficacy and safety profiles in the treatment of chronic HBV.
Total Addressable Market:
The estimated global market size for chronic HBV treatment is approximately $7 billion. For NASH, the potential market size is estimated to reach $35 billion by 2025.
Financial Performance:
Revenue: Hepion generated no revenue in 2022 or 2021.
Net Income: The company has incurred net losses in recent years due to ongoing research and development expenses. In 2022, the net loss was $14.5 million, compared to $15.7 million in 2021.
Profit Margins: Hepion currently has negative profit margins due to its pre-revenue stage.
Earnings per Share (EPS): EPS was negative in 2022 and 2021.
Year-over-Year Financial Performance Comparison:
While net income improved slightly in 2022 compared to 2021, the company continues to operate at a net loss due to research and development investments.
Cash Flow Statements and Balance Sheet Health:
Hepion primarily relies on external financing to support operations. As of December 31, 2022, the company had cash and cash equivalents of $11.7 million.
Dividends and Shareholder Returns:
Dividend History: Hepion does not yet pay dividends.
Shareholder Returns: Shareholder returns have been negative in recent years due to the company's development stage and lack of product revenue.
Growth Trajectory:
Historical Growth Analysis: Over the past 5 years, Hepion has experienced limited revenue growth as it focused on advancing its product pipeline through clinical trials.
Future Growth Projections: Future growth will depend on the successful development and commercialization of its lead product candidates. Positive clinical trial results for CPX and tigecycline could significantly impact future growth potential.
Recent Product Launches and Strategic Initiatives:
The company remains focused on advancing CPX through clinical development and regulatory approval processes. Additionally, strategic partnerships, such as the collaboration with Gilead Sciences Inc., provide further support for product development and commercialization.
Market Dynamics:
Industry Overview: The pharmaceutical industry for chronic liver diseases faces numerous challenges, primarily high research and development costs, regulatory scrutiny, and intense competition.
Competitive Landscape: Hepion competes with numerous large pharmaceutical companies and biotechnology startups developing HBV and NASH treatments.
Competitors:
- Gilead Sciences Inc. (GILD)
- Bristol Myers Squibb Company (BMY)
- Intercept Pharmaceuticals (ICPT)
Market Position: While Hepion is not yet a major player in the chronic liver disease market, it possesses a promising pipeline with potential first-in-class therapies.
Recent Acquisitions:
Hepion has not engaged in any acquisitions within the past 3 years.
AI-Based Fundamental Rating:
- Score: 4/10
- Rationale: This mid-range score reflects the company's promising product pipeline in high-value markets, counterbalanced by its pre-revenue stage, limited cash reserves, and intense competition.
Sources and Disclaimers:
- Hepion Pharmaceuticals Inc. official website: https://www.hepion.com/
- SEC Filings: https://www.sec.gov/
- Yahoo Finance: https://finance.yahoo.com/quote/HEPA/financials?p=HEPA
Disclaimer: This information should not be considered financial advice. Please consult with a qualified financial professional before making any investment decisions.
About Hepion Pharmaceuticals Inc
Exchange NASDAQ | Headquaters Edison, NJ, United States | ||
IPO Launch date 2014-02-11 | Interim CEO, Interim CFO & Chairman of the Board Mr. John Patrick Brancaccio C.P.A. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 22 | Website https://hepionpharma.com |
Full time employees 22 | Website https://hepionpharma.com |
Hepion Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development of drug therapy treatment for chronic liver diseases in the United States. It develops Rencofilstat, a cyclophilin inhibitor is in Phase 2b clinical trial to target multiple pathologic pathways involved in the progression of liver disease and treat non-alcoholic steatohepatitis (NASH), as well as preclinical studies of Rencofilstat shows reduction in liver fibrosis, liver inflammation, liver tumor burden, and titers of HBV, HCV, HDV, and HIV-1, and has demonstrated antiviral activities for hepatitis B, C, and D viruses through several mechanisms. The company was formerly known as ContraVir Pharmaceuticals, Inc. and changed its name to Hepion Pharmaceuticals, Inc. in July 2019. Hepion Pharmaceuticals, Inc. was incorporated in 2013 and is headquartered in Edison, New Jersey.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.